Single Peptides · Exact presentation
SS-31 · 10 mg Vial
SS-31 · 10 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
Dosing & Reconstitution Guide
For a 10 mg presentation, the reference concentration of 10 mg/mL mathematically corresponds to 1 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 10 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.1 mg at this concentration.
Standard / Gradual Approach (1 mL = 10 mg/mL)
The source chart summarizes “5 mg–10 mg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Approach (1 mL = 10 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 5 mg (5000 mcg) | 50 units (0.50 mL) |
| Weeks 3–8 | 10 mg (10,000 mcg) | 100 units (1.0 mL) |
Reconstitution Steps
For a 10 mg presentation, the reference concentration of 10 mg/mL mathematically corresponds to 1 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 10 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.1 mg at this concentration.
Advanced / Aggressive Approach (1 mL = 10 mg/mL)
The source chart summarizes “5 mg–10 mg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Advanced / Aggressive Approach (1 mL = 10 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 5 mg (5000 mcg) | 50 units (0.50 mL) |
| Weeks 3–4 | 10 mg (10,000 mcg) | 100 units (1.0 mL) |
| Weeks 5–8 | 15 mg (15,000 mcg) | Split: 2 × 75 units (0.75 mL each) |
| Optional Weeks 9–12 | 20 mg (20,000 mcg) | Split: 2 × 100 units (1.0 mL each) |
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
It is studied in cellular bioenergetics, mitochondrial function, substrate metabolism, or stress signaling. The specific molecular target depends on the compound.
Potential Benefits & Side Effects
A biochemical effect should not be extrapolated to a clinical outcome. Formulation, concentration, and studied population are decisive.
Potential Benefits:
Evidence includes preclinical models and, for selected agents, human trials or authorized medicines with narrowly defined indications.
Source trail
Scientific references and source discovery
- PeptideDosages — exact SS-31 · 10 mg Vial entrysecondary-structure
- PubMed — literature search for SS-31primary-discovery
- ClinicalTrials.gov — study search for SS-31trial-registry
- FDA — accelerated approval of elamipretide for Barth syndromeregulatory
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference